AEBi
Therapeutic Peptides for Personalized Cancer Treatment
Company Overview
Snapshot
Founded in June 2000 by Ilan Morad, AEBi operates with 1–10 employees. The company is engaged in the discovery and development of therapeutic peptides, holding a patent for its combinatorial biology screening platform technology.
Business overview
Accelerated Evolution Biotechnologies (AEBi) is a development-stage biopharmaceutical company focused on the discovery and development of therapeutic peptides. The company utilizes an IP-protected combinatorial biology screening platform technology to identify binders to known targets and select functional molecules. AEBi's platform is designed to discover new lead compounds for disease targets, serving the biopharmaceutical and pharmaceutical industries within the Health Tech & Life Sciences sector.
Strategic signal
In January 2019, AEBi garnered significant media attention with claims of developing a cancer cure, which were met with skepticism from various sources, including Forbes and The Times of Israel. This event highlights the company's ambitious therapeutic goals and the public scrutiny surrounding its research and development efforts in personalized cancer treatment.
Log in to access full profile ›Company Intelligence Q&A
- What is AEBi's core technology?
- AEBi has developed an IP-protected combinatorial biology screening platform technology. This platform is designed to discover new and better lead compounds to disease targets by finding binders to known targets and selecting the most functional molecules.
- When was AEBi founded and by whom?
- AEBi was founded in June 2000 by Ilan Morad, who also serves as the CEO.
- What is the primary focus of AEBi's research and development?
- AEBi is a development-stage biopharmaceutical company engaged in the discovery and development of therapeutic peptides for personalized cancer treatment.
- Where is AEBi headquartered?
- AEBi is headquartered in Ness Ziona, Israel, and was incorporated at the Weizmann Institute's ITEK technological incubator.
- Has AEBi engaged in any notable collaborations?
- AEBi has a collaboration agreement with the Israeli biopharmaceutical company Proteologics.